Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination

Christine Durier; Läétitia Ninove; Sylvie van der Werf; M. Lefèbvre; Corinne Desaint; Rebecca Bauer; Mikaël Attia; Anne-Sophie Lecompte; Marie Lachâtre; Z. Maakaroun-Vermesse; Jean‐François Nicolas; Renaud Verdon; Jean‐Jacques Kiladjian; Paul Loubet; Catherine Schmidt‐Mutter; V. Corbin; Séverine Ansart; Giovanna Melica; Martine Resch; Emmanuelle Netzer; Yousra Kherabi; Raphaëlle Tardieu; Jean‐Daniel Lelièvre; Éric Tartour; Laurence Meyer; Xavier de Lamballerie; Odile Launay

doi:10.1016/j.idnow.2024.104886

Abstract

COVID-19 vaccine breakthrough infections were frequently reported during circulation of the Omicron variant. The ANRS|MIE CoviCompareP study investigated these infections in adults vaccinated and boosted with BNT162b2 [Pfizer-BioNTech] and with/without SARS-CoV-2 infection before vaccination.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Durier et al. (2024) studied this question.

synapsesocial.com/papers/68e73ba2b6db6435876b59b2 https://doi.org/10.1016/j.idnow.2024.104886

View Full Paper

Ask AI

Bookmark

Share

Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination

Abstract

Discussion

Cite This Study

Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination

Abstract

Discussion

Cite This Study

Keep reading

Keep reading